Diana Blithe — Endo Lab

article 2022

Evaluation of ovulation and safety outcomes in a multi-center randomized trial of three 84 day ulipristal acetate regimens

·doi:10.1016/j.contraception.2022.04.002

ObjectivesTo describe ovulation inhibition and safety of daily oral ulipristal acetate (UPA) over 84 days.Study designThis multi-center phase 1 and/or 2 trial randomized participants to use oral ulipristal 10 mg or 5 mg daily or a 3 cycle r…

article 2007

Progesterone receptor modulators and the endometrium: changes and consequences†

Human Reproduction Update ·doi:10.1093/humupd/dmm023

Progesterone receptor modulators (PRMs) have been used for contraceptive research, as well as for treatment of fibroids, endometriosis and heavy or irregular menstrual bleeding. Long-term treatment with these compounds results in changes to…

article 2003

Development of the selective progesterone receptor modulator CDB-2914 for clinical indications

·doi:10.1016/s0039-128x(03)00118-1

CDB-2914 (17 alpha-acetoxy-11 beta-[4-N,N-dimethylaminophenyl]-19-norpregna-4,9-diene-3,20-dione) is a 19-norprogesterone derivative that acts as an antagonist in progesterone-responsive tissues. It binds to progesterone receptors A and B w…